Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2026 09:34 ET | Source: Research and Markets

Antibody-drug Conjugates (ADCs) in Oncology Market Competitive Landscape Report 2026: Comprehensive Insights About 200+ Companies and 220+ Drugs by Product Type, Stage, and Route of Administration

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody-drug Conjugates (ADCs) in Oncology - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering.This report...
March 03, 2026 06:38 ET | Source: Research and Markets

ADC Cytotoxic Payloads and Warheads Industry Research Report 2026-2035 - Breakthrough Cancer Therapies and Next-Generation ADC Innovations Accelerate Market Expansion

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "ADC Cytotoxic Payloads and Warheads Market (2nd Edition): Trends and Forecast Til 2035 - Distribution Type of Product, Type of Payload, Sub-Category...
February 24, 2026 07:30 ET | Source: Promatix Biosciences, Ltd.

Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity

Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based platform to optimise cis-bispecific antibody-drug conjugate...
February 23, 2026 06:12 ET | Source: Research and Markets

Antibody-Drug Conjugate Drug Market Landscape Report 2026 Featuring 34 Key Players - Past and Emerging Trends, Partnership Opportunities, Drug Pipelines, and Leading Companies

Dublin, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugate Drug Landscape" report has been added to ResearchAndMarkets.com's offering.This report investigates the impacts and...
February 20, 2026 10:56 ET | Source: Research and Markets

Glypican-3 (GPC3) Targeted Therapy Market Competitor Analysis Report 2026: More Than 20 Product Candidates are in Clinical Development and Further Eight at IND or IND-enabling Stage

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
February 20, 2026 10:55 ET | Source: Research and Markets

PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2026: PYLARIFY Exceeds US$ 1 Billion in Net Sales and Became the First Ever Blockbuster Radiodiagnostic

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics" report has been added to ResearchAndMarkets.com's offering.This competitive...
February 19, 2026 07:33 ET | Source: Research and Markets

Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030 - Novartis' Pluvicto and Lutathera Have Catalyzed Commercial Momentum

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapeutics in Cancer Treatment: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for radioligand...
February 03, 2026 07:53 ET | Source: Research and Markets

Antibody Drug Conjugates (ADC) Market Forecasts 2026-2030 with Executive and Consultant Guides - Fast-Tracking, Funding Availability, and Targeted Solutions Spurs Expansion

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Forecasts (2026-2030) by Cancer, Payload, Target, Product, User and Country/Region with Executive and Consultant...
January 19, 2026 04:07 ET | Source: Research and Markets

Global Antibody Drug Conjugates Market to Surge from USD 12.26 Billion in 2024 to USD 32.11 Billion by 2033

Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Application (Blood Cancer, Urothelial Carcinoma, Ovarian Cancer, Breast...
November 27, 2025 09:00 ET | Source: Research and Markets

B7-H3-Targeted Immunotherapy Competitor Analysis Report 2025: More Than 15 Product Candidates are in Clinical Development, with Several Already in Clinical Phase III

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "B7-H3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...